Regulation, approvals, pricing rules, and the legal fights shaping who can get these medicines.
3 articles
A federal advisory committee in 2026 was scheduled to consider whether seven popular peptides could return to a list that permits pharmacy compounding. The institutional action was a recommendation process, while the FDA retained the final decision. The people affected include consumers already encountering wellness peptides in a poorly regulated market and clinicians facing questions about products without the large human trials required for approval. The policy dispute was about the evidence threshold and the legal route to supply.
